Update shared on15 Aug 2025
As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value.
What's in the News
- ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.
- Phase 3 ENVISION trial demonstrated a 24-month duration of response rate of 72.2% in patients achieving complete response at three months, supporting ZUSDURI’s sustained efficacy and durability.
- A Phase 3b study showed that ZUSDURI can be safely and effectively administered in the home setting by trained health professionals.
- Long-term (five-year) data from the OPTIMA II trial confirmed durable, long-term complete responses for patients treated with ZUSDURI.
- UroGen is facing a class action lawsuit alleging that it misled investors regarding the design and regulatory risk of its ENVISION study for UGN-102, after the FDA and its advisory committee raised efficacy concerns, leading to significant stock declines.
Valuation Changes
Summary of Valuation Changes for UroGen Pharma
- The Consensus Analyst Price Target remained effectively unchanged, at $31.43.
- The Discount Rate for UroGen Pharma remained effectively unchanged, at 6.85%.
- The Future P/E for UroGen Pharma remained effectively unchanged, at 15.67x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.